Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
AssigneeNovartis AG
InventorsDiego Albrecht, Priyamvada Chandra, Sven Godtfredsen, Pierre Jordaan, Martin Lefkowitz
Life of this patent
Estimating the term…
Abstract
The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.
Claims18
1-14. (canceled)
A method of treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy comprising administering to said mammal:
- a) a pharmaceutical composition comprising a therapeutically effective amount of the compound of the formula:
- [(A1)(A2)](C)y·x H2O (I)
- wherein
- A1 is S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form;
- A2 is (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form;
- (Cat) is a cation;
- y is 1 to 3;
- and
- x is 0 to 3;
- or
- b) a pharmaceutical composition comprising a therapeutically effective amount of
- (i) valsartan or a pharmaceutically acceptable salt thereof;
- and
- (ii) N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionyl amino)-2-methyl-pentanoic acid or a pharmaceutically acceptable salt thereof.
A method of treating hypertension and/or preventing or treating heart failure in a human receiving anti-coagulant therapy comprising administering to said human a pharmaceutical composition comprising a therapeutically effective amount of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate, wherein the anticoagulant treatment comprises administration of warfarin or a pharmaceutically acceptable salt thereof.
A pharmaceutical combination for treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy comprising:
- a) a therapeutically effective amount of the compound of the formula:
- [(A1)(A2)](C)y·x H2O (I)
- wherein
- A1 is S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form;
- A2 is (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form;
- (Cat) is a cation;
- y is 1 to 3;
- and
- x is 0 to 3;
- or
- b) a therapeutically effective amount of
- (i) valsartan or a pharmaceutically acceptable salt thereof;
- and
- (ii) N-(3-carboxy-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-2R-methylbutanoic acid ethyl ester or (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionyl amino)-2-methyl-pentanoic acid or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.